Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Barclays PLC    BARC   GB0031348658

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

The Tamarack Advisers Lp Sells 201,000 Shares of Atricure, Inc. (Atrc)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/25/2017 | 09:42am CET

Tamarack Advisers LP lowered its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 59.8% during the third quarter, Holdings Channel reports. The firm owned 135,000 shares of the medical device companys stock after selling 201,000 shares during the period. AtriCure makes up about 0.7% of Tamarack Advisers LPs portfolio, making the stock its 24th largest position. Tamarack Advisers LPs holdings in AtriCure were worth $2,097,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the stock. BlackRock Group LTD boosted its stake in AtriCure by 5.5% in the third quarter. BlackRock Group LTD now owns 10,969 shares of the medical device companys stock worth $174,000 after buying an additional 576 shares during the period. BlackRock Advisors LLC raised its position in AtriCure by 11.5% in the second quarter. BlackRock Advisors LLC now owns 14,654 shares of the medical device companys stock worth $207,000 after buying an additional 1,517 shares in the last quarter. American International Group Inc. raised its position in AtriCure by 8.9% in the second quarter. American International Group Inc. now owns 18,093 shares of the medical device companys stock worth $256,000 after buying an additional 1,478 shares in the last quarter. Advisory Services Network LLC bought a new position in AtriCure during the third quarter worth approximately $260,000. Finally, Barclays PLC raised its position in AtriCure by 51.6% in the second quarter. Barclays PLC now owns 20,314 shares of the medical device companys stock worth $287,000 after buying an additional 6,918 shares in the last quarter. 79.35% of the stock is currently owned by institutional investors.

AtriCure, Inc. (NASDAQ:ATRC) opened at 16.47 on Monday. AtriCure, Inc. has a 52-week low of $13.44 and a 52-week high of $20.40. The firms 50-day moving average is $17.30 and its 200 day moving average is $16.83. The stocks market capitalization is $547.45 million.

A number of research analysts recently commented on the stock. Zacks Investment Research lowered shares of AtriCure from a buy rating to a hold rating in a research note on Wednesday, December 28th. Canaccord Genuity reiterated a buy rating and set a $20.00 price objective on shares of AtriCure in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $20.63.

In other AtriCure news, Director Elizabeth D. Krell sold 10,000 shares of the businesss stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $19.73, for a total value of $197,300.00. Following the transaction, the director now directly owns 24,162 shares in the company, valued at $476,716.26. The transaction was disclosed in a document filed with the SEC, which is available through this link. 10.00% of the stock is owned by insiders.

(c) 2017 ITP Business Publishing Ltd. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BARCLAYS PLC
09:42a The Tamarack Advisers Lp Sells 201,000 Shares of Atricure, Inc. (Atrc)
02/24 BARCLAYS : Form 8.5 (EPT/NON-RI) - BOOKER GROUP PLC Amendment
02/24 AerCap Holdings N.V. Announces Completion of Amendment, Extension and Upsizin..
02/24 BARCLAYS : Form 8.5 (EPT/NON-RI) DEUTSCHE BOERSE AG
02/24 EXCLUSIVE - RBC REVIEWS ASIA WEALTH : sources
02/24 BARCLAYS : profits treble as it kills off its bad bank
02/24 BARCLAYS : Form 8.5 (EPT/NON-RI) - DEUTSCHE BOERSE AG Amendment
02/24 BARCLAYS : Form 8 (DD) - TESCO PLC
02/24 BARCLAYS : Form 8.5 (ept/non-ri) - london stock exchange group plc
02/24 BARCLAYS : Form 8.5 (EPT/NON-RI) - DEUTSCHE BOERSE AG
More news
Sector news : Banks - NEC
01:38a CITIGROUP : Citi says U.S. regulators are investigating its hiring practices
12:20aDJCITIGROUP : Confirms Investigations Over 'Princelings' Hiring Practices
02/24DJIntesa Sanpaolo Won't Make Takeover Bid for Assicurazioni Generali
02/24 Sweden drops plans for bank tax, proposes higher resolution fund fee
02/24 Italian financial mega-deal off as Intesa ditches Generali plan
More sector news : Banks - NEC
News from SeekingAlpha
02/24 2 Pairs Trades You Can Take To The Bank
02/24 The Best Trump Stock
02/23 Barclays' (BCS) CEO Jes Staley on Q4 2016 Results - Earnings Call Transcript
02/23 Barclays reverses lower after earnings call
02/23 Barclays beats by 2p, misses on revenue
Advertisement
Financials ( GBP)
Sales 2017 21 926 M
EBIT 2017 7 102 M
Net income 2017 2 148 M
Debt 2017 -
Yield 2017 1,35%
P/E ratio 2017 15,94
P/E ratio 2018 10,52
Capi. / Sales 2017 1,75x
Capi. / Sales 2018 1,70x
Capitalization 38 320 M
More Financials
Chart BARCLAYS PLC
Duration : Period :
Barclays PLC Technical Analysis Chart | BARC | GB0031348658 | 4-Traders
Full-screen chart
Technical analysis trends BARCLAYS PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 24
Average target price 2,33  GBP
Spread / Average Target 3,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
James Edward Staley Chief Executive Officer & Director
John McFarlane Non-Executive Chairman
Paul H. Compton Group Chief Operating Officer
Tushar Morzaria Group Finance Director & Executive Director
Reuben Jeffery Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BARCLAYS PLC1.10%47 752
JPMORGAN CHASE & CO.5.61%323 225
WELLS FARGO & CO6.13%290 339
BANK OF AMERICA CORP11.22%243 575
INDUSTRIAL AND COMMRCL..6.80%242 076
CHINA CONSTRUCTION BAN..9.74%206 857
More Results